Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Capital Expenditures (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Capital Expenditures data on record, last reported at $1.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 63.94% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 67.04%, while the annual FY2025 figure was $1.0 million, 67.04% down from the prior year.
  • Capital Expenditures reached $1.0 million in Q4 2025 per TRDA's latest filing, up from -$1.1 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.7 million in Q1 2023 and bottomed at -$4.4 million in Q4 2023.
  • Average Capital Expenditures over 4 years is $299666.7, with a median of $838000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: skyrocketed 451.45% in 2023, then tumbled 209.37% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at -$2.1 million in 2022, then tumbled by 111.86% to -$4.4 million in 2023, then surged by 114.33% to $635000.0 in 2024, then surged by 63.94% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $1.0 million in Q4 2025, -$1.1 million in Q2 2025, and $1.1 million in Q1 2025.